PURPOSE: We investigated whether tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic information in the form of gene expression signatures that can be used to model and predict outcome of patients. PATIENTS AND METHODS: A 22,000-probe set microarray was used to evaluate 120 RMS specimens and correlate gene expression patterns to survival. Multivariate gene expression models or metagenes were developed using cross-validated Cox regression proportional hazards modeling and were evaluated using Kaplan-Meier analysis. RESULTS: A 34-metagene, based on expression patterns of 34 genes, was highly predictive of outcome. It was not highly correlated with individual clinical risk factors such as patient age, stage, tumor size, or histology. However, it was correlated with a risk classification used by the Children's Oncology Group and the biologic subsets of alveolar histology tumors. CONCLUSION: These data support further evaluation of RMS metagenes to discriminate patients with good prognosis from those with poor prognosis, with the potential to direct risk-adapted therapy.
PURPOSE: We investigated whether tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic information in the form of gene expression signatures that can be used to model and predict outcome of patients. PATIENTS AND METHODS: A 22,000-probe set microarray was used to evaluate 120 RMS specimens and correlate gene expression patterns to survival. Multivariate gene expression models or metagenes were developed using cross-validated Cox regression proportional hazards modeling and were evaluated using Kaplan-Meier analysis. RESULTS: A 34-metagene, based on expression patterns of 34 genes, was highly predictive of outcome. It was not highly correlated with individual clinical risk factors such as patient age, stage, tumor size, or histology. However, it was correlated with a risk classification used by the Children's Oncology Group and the biologic subsets of alveolar histology tumors. CONCLUSION: These data support further evaluation of RMS metagenes to discriminate patients with good prognosis from those with poor prognosis, with the potential to direct risk-adapted therapy.
Authors: R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist Journal: J Pediatr Hematol Oncol Date: 2001-05 Impact factor: 1.289
Authors: Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Anka Thies; Melitta Schachner; Ingrid Moll; Jürgen Berger; Hans-Joachim Schulze; Georg Brunner; Udo Schumacher Journal: Eur J Cancer Date: 2002-09 Impact factor: 9.162
Authors: Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche Journal: Am J Pathol Date: 2009-01-15 Impact factor: 4.307
Authors: John C Breneman; Elizabeth Lyden; Alberto S Pappo; Michael P Link; James R Anderson; David M Parham; Stephen J Qualman; Moody D Wharam; Sarah S Donaldson; Harold M Maurer; William H Meyer; K Scott Baker; Charles N Paidas; William M Crist Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Stephen J Qualman; Jay Bowen; David M Parham; Philip A Branton; William H Meyer Journal: Arch Pathol Lab Med Date: 2003-10 Impact factor: 5.534
Authors: Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic Journal: Clin Cancer Res Date: 2012-05-30 Impact factor: 12.531
Authors: Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2013-03-22 Impact factor: 3.167
Authors: Amit J Sabnis; Christopher J Guerriero; Victor Olivas; Anin Sayana; Jonathan Shue; Jennifer Flanagan; Saurabh Asthana; Adrienne W Paton; James C Paton; Jason E Gestwicki; Peter Walter; Jonathan S Weissman; Peter Wipf; Jeffrey L Brodsky; Trever G Bivona Journal: Proc Natl Acad Sci U S A Date: 2016-07-22 Impact factor: 11.205